Analytical Data
-
Gene name
LPAR2
- Application
-
Alternative Names
LPAR2; EDG4; LPA2; Lysophosphatidic acid receptor 2; LPA receptor 2; LPA-2; Lysophosphatidic acid receptor Edg-4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HBW0
-
Expression Region
1-348aa
-
AA Sequence
MGQCYYNETIGFFYNNSGKELSSHWRPKDVVVVALGLTVSVLVLLTNLLVIAAIASNRRFHQPIYYLLGNLAAADLFAGVAYLFLMFHTGPRTARLSLEGWFLRQGLLDTSLTASVATLLAIAVERHRSVMAVQLHSRLPRGRVVMLIVGVWVAALGLGLLPAHSWHCLCALDRCSRMAPLLSRSYLAVWALSSLLVFLLMVAVYTRIFFYVRRRVQRMAEHVSCHPRYRETTLSLVKTVVIILGAFVVCWTPGQVVLLLDGLGCESCNVLAVEKYFLLLAEANSLVNAAVYSCRDAEMRRTFRRLLCCACLRQSTRESVHYTSSAQGGASTRIMLPENGHPLMDSTL
-
Molecular Weight
38.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LPAR2 (Lysophosphatidic Acid Receptor 2) is a member of the G protein-coupled receptor family that plays a crucial role in various physiological processes, including cell proliferation, survival, migration, and differentiation. The research on LPAR2 has gained momentum due to its implications in several diseases, particularly cancer, fibrotic disorders, and neurological conditions. Lysophosphatidic acid (LPA), the endogenous ligand for LPAR2, is involved in several signaling pathways that can influence tumor microenvironments, contributing to cancer progression and metastasis. Given its significant role in these pathways, LPAR2 has emerged as a potential therapeutic target. Studies have shown that modulating LPAR2 activity can alter cellular responses in various contexts, making it an important subject of investigation for the development of novel treatments. Researchers are exploring LPAR2’s structure, function, and signaling mechanisms to better understand its role in disease and to identify small molecules or biologics that can selectively target this receptor. The elucidation of LPAR2 signaling pathways also offers insights into the broader field of signaling biology, making it an attractive target for drug discovery. Overall, the characterization and manipulation of LPAR2 through recombinant protein techniques and other biochemical approaches could pave the way for innovative therapeutic strategies in treating LPA-associated diseases.
